2023-508572-11-00招募中3 期
Systemic Targeted Adaptive RadioTherapy of NeuroEndocrine Tumors. An open-label, multi-center, randomized phase III trial comparing safety and efficacy of personalized vs non-personalized radionuclide therapy with 177Lu-DOTATOC
试验速览
- 阶段
- 3 期
- 状态
- 招募中
- 发起方
- Region Skane
- 入组人数
- 300
- 试验地点
- 4
- 主要终点
- Median PFS defined as time from randomization to radiological progression, or death from any cause
研究概览
简要总结
The primary objective of this study is to compare the efficacy of personalized vs nonpersonalized PRRT with 177Lu-DOTATOC in patients with SSTR-positive NET G1-G3.
研究设计
- 分配方式
- Randomized
- 主要目的
- Sstr++, Progressive, Advanced Net G1-g3
- 盲法
- None
入排标准
- 年龄范围
- 18 years 至 65+ years（18-64 Years, 65+ Years）
- 接受健康志愿者
- 是
入选标准
- •The subject has given written informed consent to participate in the study.
- •Given the available, approved anti-tumor treatments and the specific characteristics of the patient and the tumor, the investigator judges PRRT to be the treatment of choice
- •GFR > 50 ml/min/1.73 m2 as determined by iohexol- or 51Cr-EDTA clearance, calculated according to a combination of LMR18 and CAPA formulas, or equally accurate method
- •Adequate hematological parameters as defined by: Hemoglobin > 90 g/L, platelets >100 x109/L, leukocytes > 3.0x109/L, neutrophils > 1.5 x109/L
- •Adequate hepatic function as defined by ASAT/ALAT < 3 x ULN, bilirubin < 2 x ULN, albumin > 25 g/L.
- •For women of child-bearing potential, highly effective contraception should be usedfrom the time of inclusion up to at least six months after the EOT visit. For details see appendix
- •For male subjects living with a woman of child-bearing potential, adequate contraception should be used from the time of inclusion up to at least six months after the EOT visit. Adequate male contraception methods are vasectomy, surgical or pharmacological castration, or the use of condom during heterosexual intercourse.
- •Age ≥18 years
- •ECOG performance status 0-1
- •Life expectancy > 3 months.
- •Presence of histologically confirmed, advanced, well-differentiated, inoperable NETof any primary tumor origin (except pheochromocytoma and paraganglioma) and any grade, with a maximum Ki67 of 50%
- •SSTR-expression (mean SUV) in tumor lesions ≥ 2x mean SUV in normal liver on 68Ga-DOTA-PET performed ≤ 6 months prior to randomization. Due to partial volume effects, tumor lesions smaller than 1 cm on CT or MRI should not be used to evaluate this eligibility criterium.
- •Radiologically progressive disease within the last 1-24 months according to common clinical criteria and confirmed by the institutional multidisciplinary conference for the treatment of NETs. The CT/MRI that shows tumor progression compared to screening/baseline must have been performed 1-24 months earlier.
- •All previous anti-tumor treatment except SSA must be terminated at least 4 weeks before start of treatment within the trial
- •Measurable disease according to RECIST v 1.1
排除标准
- •Pregnancy or lactation
- •Previous radiotherapy of any kind which has resulted in irradiation of both kidneys and/or > 50% of the red bone marrow.
- •Any other serious, uncontrolled medical or psychiatric condition including other advanced or metastatic malignant disease that, in the opinion of the investigator, precludes the patient from participation in the trial
- •Mental inability, reluctance or language difficulties that result in difficulty understanding the meaning of study participation
- •Inability or reluctance to adhere to the radiation safety instructions
- •Previous treatment with PRRT for NET
- •Concomitant systemic anti-tumor therapy other than SSA
- •Participation or recent participation in a clinical study with an investigational product within 30 days of randomization.
- •Known hypersensitivity to edotreotide, octreotide, capecitabine or any of the excipients included in the preparations.
- •Contraindications for treatment with capecitabine: a. Severe arterial thromboembolic events (myocardial infarction,unstable angina pectoris, stroke) less than 6 months before inclusion. b. New York Heart Association (NYHA) Class III or IV congestive heart failure, ventricular arrhythmias or uncontrolled blood pressure c. Previous serious or unexpected reactions to fluoropyrimidine treatment d. Known complete deficiency of dihydropyrimidine dehydrogenase (DPD) e. Recent or concomitant treatment with brivudine
- •Discordance between CT/MRI/18F-FDG-PET and 68Ga-DOTA-PET, with evidence of tumor lesions without uptake on 68Ga-DOTA-PET
- •Liver-directed therapy of metastases (i.e. radioembolization, chemoembolization, radiofrequency ablation, surgery, etc) < 4 weeks prior to randomization.
- •Major surgery < 12 weeks prior to randomization.
结局指标
主要结局
Median PFS defined as time from randomization to radiological progression, or death from any cause
Median PFS defined as time from randomization to radiological progression, or death from any cause
次要结局
- Rate of treatment-related adverse reactions graded according to CTCAE v5.0
- Median OS defined as time from randomization to death from any cause
- Median PFS defined as time from randomization to radiological progression, or death from any cause
- Percent change in SLD from baseline to time of best response
- EORTC QoL-questionnaires GI-NET21
- Cumulative median AD to target tumor lesions in subjects with CR, PR, SD and PD as best response, according to RECIST evaluations
- Correlation between cumulative median AD to target tumor lesions and time to progression, defined as time from randomization to radiological progression.
- Cumulative median AD and BED to kidneys vs rate of grade 3-4 renal toxicity (estimated and measured GFR)
- Differences in resource utilization and treatment cost between the two treatment arms, in relation to the respective mPFS and mOS.
研究者
Pernilla Asp
Scientific
Region Skane
研究点 (4)
Loading locations...
相似试验
招募中
3 期
Systemic Targeted Adaptive RadioTherapy of NeuroEndocrine Tumors.Neuroendocrine TumorsNCT05387603Lund University Hospital300
招募中
不适用
Efficacy Analysis of Personalized-Target Transcranial Magnetic Stimulation (TMS) in the Treatment of Chronic Tinnitus: A Single-Center, Single-Blind Randomized Clinical TrialChronic TinnitusNCT07267455Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University116
进行中（未招募）
1 期
START-NET: A randomized clinical trial to compare personalized vs non-personalized radionuclide therapy with 177Lu-DOTATOCPatients with SSTR+, advanced, progressive NET Grade 1-3 of any origin for whom Peptide-receptor radionuclide therapy, PRRT, is considered the mostappropriate treatment option in relation to other approved or available investigational agents for the specific tumor subtype.MedDRA version: 21.0Level: LLTClassification code 10062476Term: Neuroendocrine tumorSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2021-002218-15-SERegion Skåne300
招募中
2 期
Study evaluating PSMA targeted radionuclide therapy in adult patients with metastatic clear cell renal cancer2022-502440-12-00Centre Leon Berard, Centre Leon Berard, Centre Leon Berard48
招募中
不适用
RADprecise - Personalized radiotherapy: incorporating cellular response to irradiation in personalized treatment planning to minimize radiation toxicityC50C61Malignant neoplasm of breastMalignant neoplasm of prostateDRKS00020290Deutsches Krebsforschungszentrum (DKFZ) / German Cancer Research Center1,050